In certain embodiments, a compound of Formula 1 or a pharmaceutical composition comprising a compound of Formula 1 may be administered in conjunction with one or more agents known or believed to be a VEGFR vascular endothelial growth factor receptor inhibitor, a RTK receptor tyrosine kinase inhibitor, a sodium channel current blocker, aFAK focal adhesion kinase inhibitor, a GLI glioma associated oncogene inhibitor, a GLI1 inhibitor, a GLI2 inhibitor, a GLI3 inhibitor, a MAPK mitogen activated protein kinase inhibitor, a MAPK ERK pathway also known as Ras Raf MEK ERK pathways inhibitor, a MEK1 inhibitor, a MEK2 inhibitor, a MEK5 inhibitor, a MEK5 ERK5 inhibitor, aRTA renal tubular acidosis inhibitor, a ALK anaplastic lymphoma kinase inhibitor, Aa LK kinase inhibitor, a nuclear translocation inhibitor, a PORCN porcupine inhibitor, a 5 ARI 5О± reductase inhibitor, topoisomerase inhibitor, a Ras rat sarcoma inhibitor, a K ras inhibitor, a CERK ceramide kinase inhibitor, a PKB protein kinase B, also known as AKT inhibitor, a AKTI inhibitor, EZH2 enhancer of zeste homolog 2 inhibitor, a BET bromodomain and extraterminal domain motif inhibitor, a SYK spleen tyrosine kinase inhibitor, JAK janus kinase inhibitors, a SYK JAK inhibitor, a IDO indoleamine pyrrole 2, 3 dioxygenase inhibitor, a IDO1 inhibitor, a RXR retinoic X receptors activating agent, a selectively RXR activating agent, a p glycoprotein inhibitor, a ERK inhibitor, a PI3K phosphatidylinositol 4, 5 bisphosphate 3 kinase inhibitor, a BRD bromodomain containing protein inhibitor, a BRD2 inhibitor, a BRD3 inhibitor, a BRD4 inhibitor, a BRDT bromodomain testis specific protein inhibitor, a reverse transcriptase inhibitor, a NRT nucleoside analog reverse transcriptase inhibitor, a PIM proviral integrations of monkey virus inhibitor, a EGFR epidermal growth factor receptor inhibitor, a photosensitizer, a radiosensitizer, a ROS proto oncogene, recptor tyrosine kinase inhibitor, a ROS 1 proto oncogene 1 inhibitor, a CK caseine kinase inhibitor, a CK2 inhibitor, a Bcr Abl breakpoint cluster region Abelson proto oncogene tyrosine kinase inhibitor such as dasatinib, a microtubule stabilizing agent, a microtubule depolymerisation disassembly inhibitor, a DNA intercalator, an androgen receptor antagonist, a chemoprotective agents, a HDAC histone deacetylase inhibitor, a DPP dipeptidyl pepdidase inhibitor, a DPP 4 inhibitor, BTK Bruton s tyrosine kinase inhibitor, a kinase inhibitor such as imatinib, a tyrosine kinase inhibitor such as nilotinib, a ARP poly ADP ribose polymerase inhibitor, a CDK cyclin dependent kinase inhibitor, a CDK4 inhibitor, a CDK6 inhibitor, a CDK4 6 inhibitor, a HIF1О± hypoxia inducible factor 1 О± inhibitor, a DNA ligase inhibitor, a DNA ligase IV inhibitor, a NHEJ non homologous end joining inhibitor, a DNA ligase IV, a NHEJ inhibitor and a RAF inhibitor, a TKI and a RAF inhibitor, a TKI and RAF inhibitor such as sorafenib, a PDT photodynamic therapy sensitizer, an ATR ataxia telangiectasia and Rad3 related protein kinase inhibitor, or a combination of any of the foregoing <a href=http://clomid.mom/>clomiphene for men</a>
